Your browser is out of date. Some of the content on this site will not work properly as a result.
Upgrade your browser for a faster, better, and safer web experience.

Christmas subscriptions to Delayed Gratification make the perfect present

Moment that mattered: Huntington’s disease is successfully treated for the first time

In September a breakthrough was announced in the treatment of Huntington’s disease. In initial results from an international trial funded by US biotech company UniQure, a pioneering gene therapy had been shown to slow progress of the disease in a small cohort of patients by 75 percent after three years. It was promising news for the hundreds of thousands of people around the world affected by the hereditary genetic illness which shares some features with neurodegenerative conditions such as motor neurone disease (MND), Parkinson’s and dementia. “Nobody knew this announcement was coming out, except for UniQure,” says Professor Anne Rosser, a key member of the team behind the trial. “It was a surprise to almost everybody else.”

As co-principal investigator for the UK arm of the study along with UCL professor Ed Wild, Rosser’s responsibilities included recruiting patients and following them through the treatment journey. Neurosurgeon and chief investigator professor William Gray and his team, meanwhile, delivered the gene therapy to patients in the UK. All were caught off guard by September’s announcement as they did not know the results from parallel programmes in Poland and the US until UniQure issued a press release. “As is common practice in these kinds of clinical trials, UniQure were not allowed to share the full results with anyone beforehand, because that might lead to accusations of insider trading,” explains Rosser. “As an investigator in the trial it was a slightly strange thing, because suddenly there was this amazing news and we’ve all been working really hard to digest it. It was a bombshell – but in a good way.”

Huntington’s disease, or HD, has long been one of medicine’s biggest mysteries. The condition is caused by a single faulty gene and steadily kills cells in specific areas of the brain, leading to dementia, incapacity and ultimately death. The first symptoms usually appear in a person’s thirties or forties and include mood swings, anger and depression. As the illness progresses, patients develop uncontrollable jerky movements, cognitive decline and personality change. They eventually lose the ability to live independently. Many die within two decades of diagnosis. Due to its hereditary nature, anyone with an affected parent has a 50 percent chance of developing the disease. Approximately 75,000 people have HD in the UK, US and Europe, with many more carrying the faulty gene.

Rosser has been working on the disease since the mid-’90s. “You end up looking after people over the years, and they start to deteriorate, and then you’ve got their children coming along who might suffer the same fate,” she says. “It’s an incredibly high-burden disease and you really understand the need for this community to have a treatment.” But despite the gene that causes HD having been identified in 1993, research scientists have been unable to find any such treatment – until now.

The therapy announced in September is far from straightforward, however. Gray and his dedicated surgical team in Cardiff had spent years setting up the only site in the UK – and one of only a few worldwide – with the capability of carrying out such a groundbreaking surgical trial. It involved injecting a genetically-modified virus directly into the brain during a 12-14 hour procedure carried out within an MRI scanner. This virus then spread through the brain cells and lowered the levels of the mutant protein, huntingtin, that causes Huntington’s.

“We all have two copies of the Huntington gene,” explains Rosser. “If you have HD, you have one normal copy and one copy that’s mutated and produces a mutation of the huntingtin protein which is slightly toxic to the cells in the body. They can cope with this toxicity up to a point, which is why HD starts in middle age, not infancy, but eventually they start failing. The treatment that was delivered in this trial is basically a tiny bit of DNA, a gene, which lowers the levels of huntingtin protein in the brain and that allows the cells to recover and start functioning better.” The DNA activates neurons in the brain to start producing a therapeutic molecule which intercepts and neutralises the RNA that carries instructions for making the faulty protein. “It’s delivered within a modified virus, because viruses are good at getting into cells, whereas genes on their own could not efficiently get into a cell,” says Rosser.

While the announcement of the success of the trial may have taken everyone – including Rosser – by surprise, the professor is keen to stress that this treatment did not arrive out of nowhere. “One of the things that the Huntington’s field has done is a massive observational study, called Enroll-HD, that has been funded by the CHDI Foundation [a US biomedical non-profit dedicated to tackling HD],” she says. “That has collected data over two decades on over 30,000 patients and has been unbelievably powerful in helping people understand the disease better and learn how to do effective clinical trials. This breakthrough hasn’t come out of the blue at all, it’s been a massive effort over many, many years.”

Rosser also stresses the contribution of the HD sufferers who volunteered to undergo the experimental treatment. “These are very brave souls,” she says. “Once we’ve put this treatment into the brain, we can’t take it out. They had to make this difficult decision, because not only might this not work, it might also produce harm. We were very upfront with people and said that while all the animal studies suggest this is safe, we can’t guarantee that. That they’re willing to take that risk tells us what a horrendous disease this is.” Rosser believes many volunteered to help the next generation. “Often they’ve got children or nephews or nieces who are at risk. They want to contribute to eventually finding a therapy.”

While Rosser is optimistic about September’s announcement, she stresses the need for caution. “The news stories suggested the disease is cured, and it’s not nearly as straightforward as that,” she warns. “We are really excited about this result, but it’s preliminary. The full scientific paper hasn’t been published yet. It should come out in early 2026, and everyone is keen to examine all the data in a really detailed way. Obviously, as a piece of science, it’s also important that it goes through that proper scrutiny.”

Although the treatment is delivered in a single surgical procedure, it is likely to be expensive, with previous gene therapies costing more than £1 million per patient. The next step is getting approval from the US Food and Drug Administration (FDA). But in November 2025 the FDA announced that it needed to see more evidence the new therapy works. This saw UniQure’s stock price plummet by 66 percent, although its CEO Matt Kapusta says the company remains “fully committed to working with the FDA to determine the best path forward.”

Although Rosser is disappointed with the FDA announcement, she stresses this isn’t the end for UniQure or other therapeutic products. “This [treatment] isn’t the only thing that’s shown some positive signals in HD,” says Rosser. “There are other trials looking at alternative huntingtin protein-lowering methods, as well as some looking at completely different approaches, such as an oral drug, pridopidine, which stimulates a molecule on the cell surface and is showing some promise. Importantly, the UniQure trial has shown that it is possible to slow the deterioration in HD through huntingtin-lowering, and that provides hope.”

And not just hope for HD sufferers. Rosser is optimistic that the pioneering approach could also lead to breakthroughs in the treatment of other diseases. “I think it’s entirely possible that some of the solutions that are being developed for Huntington’s may be directly applicable to other diseases that share some of the underlying mechanisms such as myotonic dystrophy, or some forms of MND,” she says. For now, though, she is just happy to see progress being made against a cruel condition she has studied for more than 30 years. “I’ve been working in this field for so long, you do sort of think, ‘Will I retire before there’s any movement here?’” she says. “The really exciting thing about the UniQure result is it gives us proof of principle that, yes, this condition really can be treated. For this community that means everything.”

We hope you enjoyed this sample feature from issue #60 of Delayed Gratification

Buy issue Subscribe

More stories...

A slower, more reflective type of journalism”
Creative Review

Jam-packed with information... a counterpoint to the speedy news feeds we've grown accustomed to”
Creative Review

A leisurely (and contrary) look backwards over the previous three months”
The Telegraph

Quality, intelligence and inspiration: the trilogy that drives the makers of Delayed Gratification”
El Mundo

Refreshing... parries the rush of 24-hour news with 'slow journalism'”
The Telegraph

A very cool magazine... It's like if Greenland Sharks made a newspaper”
Qi podcast

The UK's second-best magazine” Ian Hislop
Editor, Private Eye
Private Eye Magazine

Perhaps we could all get used to this Delayed idea...”
BBC Radio 4 - Today Programme